Budesonide and risk of pneumonia

The Lancet

Volumn 374, Issue 9707, 2009, Pages 2050-

  Singanayagam, Aran ^a   Chalmers, James D ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE; PLACEBO;

ANTIBIOTIC THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG SAFETY; HUMAN; LETTER; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR;

EID: 72049108059     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)62144-9     Document Type: Letter

References (5)

1. Sin D.D., Tashkin D., Zhang X., et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 374 (2009) 712-719
2. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
3. Barbier M., Agusti A., and Alberti S. Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 32 (2008) 1283-1288
4. Hill A.T., Campbell E.J., Hill S.L., Bayley D.L., and Stockley R.A. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 109 (2000) 288-295
5. White A.J., Gompertz S., Bayley D.L., et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 58 (2003) 680-685